Petros Perros

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1110618/publications.pdf

Version: 2024-02-01

191 papers	11,210 citations	34105 52 h-index	31849 101 g-index
195 all docs	195 docs citations	195 times ranked	7683 citing authors

#	Article	IF	Citations
1	Guidelines for the management of thyroid cancer. Clinical Endocrinology, 2014, 81, 1-122.	2.4	961
2	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
3	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	3.7	611
4	The Codon 620 Tryptophan Allele of the Lymphoid Tyrosine Phosphatase (LYP) Gene Is a Major Determinant of Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5862-5865.	3.6	416
5	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
6	Frequency of Thyroid Dysfunction in Diabetic Patients: Value of Annual Screening. Diabetic Medicine, 1995, 12, 622-627.	2.3	312
7	Cognitive Ability and Brain Structure in Type 1 Diabetes. Diabetes, 2003, 52, 149-156.	0.6	270
8	Pituitary Apoplexy: A Review of Clinical Presentation, Management and Outcome in 45 Cases. Pituitary, 2004, 7, 157-163.	2.9	268
9	Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. British Journal of Ophthalmology, 2007, 91, 455-458.	3.9	253
10	Clinical assessment of patients with Gravesâ€™ orbitopathy: the European Group on Gravesâ€™ Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology, 2006, 155, 387-389.	3.7	247
11	Age and gender influence the severity of thyroidâ€associated ophthalmopathy: a study of 101 patients attending a combined thyroidâ€eye clinic. Clinical Endocrinology, 1993, 38, 367-372.	2.4	218
12	Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. Diabetes Care, 2005, 28, 1431-1437.	8.6	208
13	The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics, 1999, 8, 1195-1199.	2.9	203
14	Natural history of thyroid associated ophthalmopathy. Clinical Endocrinology, 1995, 42, 45-50.	2.4	196
15	Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. European Journal of Endocrinology, 2003, 148, 491-495.	3.7	187
16	Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology and Otology, 2016, 130, S150-S160.	0.8	184
17	Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clinical Endocrinology, 2001, 55, 283-303.	2.4	160
18	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	3.1	154

#	Article	IF	Citations
19	Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology, 2016, 84, 799-808.	2.4	149
20	Rising Serum 25-Hydroxy-Vitamin D Levels after Weight Loss in Obese Women Correlate with Improvement in Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4251-4257.	3.6	140
21	A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Gravesâ€™ Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5321-5323.	3.6	139
22	Brain Abnormalities Demonstrated by Magnetic Resonance Imaging in Adult IDDM Patients With and Without a History of Recurrent Severe Hypoglycemia. Diabetes Care, 1997, 20, 1013-1018.	8.6	130
23	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	11.4	128
24	Autoantibodies to Igf-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity, 1993, 16, 251-257.	2.6	119
25	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet, The, 1999, 354, 743-744.	13.7	119
26	Gravesâ€™ orbitopathy as a rare disease in Europe: a European Group on Gravesâ€™ Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases, 2017, 12, 72.	2.7	113
27	Genomic Polymorphism at the Interferon-Induced Helicase (IFIH1) Locus Contributes to Gravesâ€™ Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3338-3341.	3.6	104
28	Erectile Dysfunction in Patients with Hyper- and Hypothyroidism: How Common and Should We Treat?. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1815-1819.	3.6	103
29	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-Related Cancer, 2018, 25, 309-322.	3.1	103
30	A New Assay for Thyrotropin Receptor Autoantibodies. Thyroid, 2004, 14, 830-835.	4.5	95
31	Psychological implications of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2007, 157, 127-131.	3.7	95
32	PREGO (presentation of Gravesâ€™ orbitopathy) study: changes in referral patterns to European Group On Gravesâ€™ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	3.9	92
33	Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clinical Endocrinology, 2006, 65, 186-190.	2.4	82
34	Natural History of Thyroid Eye Disease. Thyroid, 1998, 8, 423-425.	4.5	81
35	Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5910-5915.	3.6	81
36	A New Assay for Thyrotropin Receptor Autoantibodies. Thyroid, 2004, 14, 830-835.	4.5	78

#	Article	IF	Citations
37	Altered Taste Sensation in Newly-Diagnosed NIDDM. Diabetes Care, 1996, 19, 768-770.	8.6	76
38	Association Analysis of the Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Autoimmune Regulator-1 (AIRE-1) Genes in Sporadic Autoimmune Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 688-691.	3.6	73
39	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	4.5	72
40	Thyroid eye disease. BMJ: British Medical Journal, 2009, 338, b560-b560.	2.3	71
41	Azathioprine in the treatment of thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1990, 122, 8-12.	3.7	69
42	A questionnaire survey on the management of Gravesâ€™ orbitopathy in Europe. European Journal of Endocrinology, 2006, 155, 207-211.	3.7	68
43	Evidence for a New Graves Disease Susceptibility Locus at Chromosome 18q21. American Journal of Human Genetics, 2000, 66, 1710-1714.	6.2	64
44	The effect of B cell depletion therapy on antiâ€<scp>TSH</scp> receptor antibodies and clinical outcome in glucocorticoidâ€refractory Graves' orbitopathy. Clinical Endocrinology, 2013, 79, 437-442.	2.4	64
45	SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Familial Cancer, 2009, 8, 257-260.	1.9	61
46	CTLA4 gene and Gravesâ€™ disease: association of Gravesâ€™ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clinical Endocrinology, 2003, 58, 732-735.	2.4	60
47	Predictive score for the development or progression of Gravesâ€™ orbitopathy in patients with newly diagnosed Gravesâ€™ hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	3.7	59
48	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Gravesâ€™ orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	3.3	57
49	New Therapeutic Horizons for Gravesâ€™ Hyperthyroidism. Endocrine Reviews, 2020, 41, 873-884.	20.1	56
50	Role of the CD40 Locus in Graves' Disease. Thyroid, 2004, 14, 506-509.	4.5	55
51	Primary hypothyroidism and quality of life. Nature Reviews Endocrinology, 2022, 18, 230-242.	9.6	55
52	Non-islet cell tumour-associated hypoglycaemia: 111 In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clinical Endocrinology, 1996, 44, 727-731.	2.4	54
53	Evidence for a Gravesâ€™ Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 626-630.	3.6	54
54	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 626-630.	3.6	54

#	Article	IF	Citations
55	Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively?. , 1997, 14, 482-486.		53
56	Further Evidence for a Susceptibility Locus on Chromosome 20q13.11 in Families with Dominant Transmission of Graves Disease. American Journal of Human Genetics, 1999, 65, 1462-1465.	6.2	53
57	Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. Clinical Endocrinology, 2021, 94, 513-520.	2.4	53
58	Clinical Presentation of Thyroid Associated Orbitopathy. Thyroid, 1998, 8, 427-428.	4.5	51
59	The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. European Journal of Endocrinology, 2009, 161, 483-487.	3.7	51
60	Thyroid disease and male reproductive function. Journal of Endocrinological Investigation, 2003, 26, 372-380.	3.3	50
61	Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabetic Medicine, 2000, 17, 749-751.	2.3	49
62	Early Response to Intravenous Glucocorticoids for Severe Thyroid-Associated Ophthalmopathy Predicts Treatment Outcome. Journal of Ocular Pharmacology and Therapeutics, 2005, 21, 328-336.	1.4	46
63	What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Gravesâ€™ disease. European Journal of Endocrinology, 2006, 154, 783-786.	3.7	44
64	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease, 2016, 48, 552-558.	0.9	44
65	New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?. Thyroid, 2021, 31, 193-201.	4.5	43
66	Tremelimumab-Induced Graves Hyperthyroidism. European Thyroid Journal, 2017, 6, 167-170.	2.4	42
67	Mortality from thyroid cancer in patients with hyperthyroidism: the Theagenion Cancer Hospital experience. European Journal of Endocrinology, 2008, 159, 799-803.	3.7	41
68	Measurement of cell proliferation by enzymeâ€linked immunosorbent assay (ELISA) using a monoclonal antibody to bromodeoxyuridine. Cell Proliferation, 1991, 24, 517-523.	5.3	40
69	Demonstration of thyrotropin binding sites in orbital connective tissue: Possible role in the pathogenesis of thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 1994, 17, 163-170.	3.3	40
70	Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 115-135.	1.0	40
71	The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary, 2015, 18, 568-574.	2.9	40
72	Pilot of <scp>BRAF</scp> mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology, 2014, 25, 146-154.	0.7	37

#	Article	IF	Citations
73	Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement. BMJ: British Medical Journal, 2001, 323, 332-333.	2.3	36
74	Weight gain following treatment of hyperthyroidismâ€”A forgotten tale. Clinical Obesity, 2019, 9, e12328.	2.0	34
75	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey. European Thyroid Journal, 2020, 9, 25-31.	2.4	34
76	Management of patients with Gravesâ€™ orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical Medicine, 2015, 15, 173-178.	1.9	33
77	The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clinical Endocrinology, 2023, 98, 461-468.	2.4	33
78	Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma. Cancer, 2003, 98, 41-47.	4.1	31
79	Serum Thyrotropin is a Better Predictor of Future Thyroid Dysfunction Than Thyroid Autoantibody Status in Biochemically Euthyroid Patients with Diabetes: Implications for Screening. Thyroid, 2004, 14, 853-857.	4.5	31
80	Residual Adrenal Function in Autoimmune Addison's Disease: Improvement After Tetracosactide (ACTH_{1â€“24}) Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 111-118.	3.6	31
81	The Amsterdam Declaration on Graves' Orbitopathy. Thyroid, 2010, 20, 245-246.	4.5	30
82	Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes/Metabolism Research and Reviews, 1999, 15, 5-12.	4.0	29
83	Use of Somatostatin Analogues in Obesity. Drugs, 2008, 68, 1963-1973.	10.9	28
84	Fatal inflammatory hypophysitis. Pituitary, 2007, 10, 107-111.	2.9	27
85	A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. Eye, 2018, 32, 1555-1562.	2.1	26
86	The Long-Term Sequelae of Severe Hypoglycemia on the Brain in Insulin-Dependent Diabetes Mellitus. Hormone and Metabolic Research, 1997, 29, 197-202.	1.5	25
87	Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. Diabetic Medicine, 2000, 17, 807-809.	2.3	25
88	Thyroid-Associated Orbitopathy: Who and How to Treat. Endocrinology and Metabolism Clinics of North America, 2009, 38, 373-388.	3.2	25
89	The pathogenesis of thyroid-associated ophthalmopathy. Journal of Endocrinology, 1989, 122, 619-624.	2.6	24
90	Thyroglobulin in differentiated thyroid cancer. Clinica Chimica Acta, 2015, 444, 310-317.	1.1	24

#	Article	IF	Citations
91	DIFFERENTIATION OF AUTOIMMUNE OPHTHALMOPATHY FROM GRAVESâ€™ HYPERTHYROIDISM BY ANALYSIS OF GENETIC MARKERS. Clinical Endocrinology, 1988, 28, 601-610.	2.4	24
92	Apolipoprotein-E Influences Aspects of Intellectual Ability in Type 1 Diabetes. Diabetes, 2003, 52, 145-148.	0.6	23
93	Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS questionnaire survey of members of the Danish Endocrine Society. Journal of Endocrinological Investigation, 2021, 44, 2435-2444.	3.3	23
94	Plasma endothelin response to acute hypoglycaemia in adults with TypeÂ1 diabetes. Diabetic Medicine, 2007, 24, 1039-1042.	2.3	22
95	Severe Thyroid Eye Disease Associated with Primary Hypothyroidism and Thyroid-Associated Dermopathy. Thyroid, 1999, 9, 1115-1118.	4.5	21
96	Chronic Pontine Dysfunction Following Insulin-Induced Hypoglycemia in an IDDM Patient. Diabetes Care, 1994, 17, 725-727.	8.6	20
97	Novel Thermal Imaging Analysis Technique for Detecting Inflammation in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4600-4606.	3.6	20
98	Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. European Thyroid Journal, 2014, 3, 245-251.	2.4	20
99	Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1. European Endocrinology, 2019, 15, 95.	1.5	19
100	Cushing's syndrome without excess cortisol. BMJ: British Medical Journal, 2006, 332, 469-470.	2.3	18
101	Introduction to the updated guidelines on the management of thyroid cancer. Clinical Medicine, 2007, 7, 321-322.	1.9	18
102	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians. *THESIS: Treatment of hypothyroidism in Europe by specialists: an international survey. Endokrynologia Polska, 2021, 72, 357-365.	1.0	18
103	Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes/Metabolism Research and Reviews, 2000, 16, 211-216.	4.0	17
104	Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester. Clinical Endocrinology, 2001, 54, 559-561.	2.4	17
105	Pathogenetic mechanisms in thyroidâ€associated ophthalmopathy. Journal of Internal Medicine, 1992, 231, 205-211.	6.0	16
106	Pathogenesis of thyroid-associated ophthalmopathy. Trends in Endocrinology and Metabolism, 1993, 4, 270-275.	7.1	16
107	Management of Gravesâ€™ orbitopathy in Latin America: an international questionnaire study compared with Europe. Clinical Endocrinology, 2008, 69, 951-956.	2.4	16
108	European Thyroid Association Guidelines on L-T4 + L-T3 Combination for Hypothyroidism: A Weary Step in the Right Direction. European Thyroid Journal, 2012, 1, 51-54.	2.4	16

#	Article	IF	Citations
109	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society. Frontiers in Endocrinology, 2021, 12, 795111.	3.5	16
110	An Audit of Waiting Times in the Diabetic Outpatient Clinic: Role of Patientsâ€™ Punctuality and Level of Medical Staffing. Diabetic Medicine, 1996, 13, 669-673.	2.3	15
111	Factors influencing preference of insulin regimen in people with type 1 (insulinâ€“dependent) diabetes. Diabetes Research and Clinical Practice, 1998, 39, 23-29.	2.8	15
112	Thyroid autoimmunity, infertility and miscarriage. Expert Review of Endocrinology and Metabolism, 2008, 3, 127-136.	2.4	15
113	Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. Nuclear Medicine Communications, 2018, 39, 834-838.	1.1	15
114	Asymmetry indicates more severe and active disease in Gravesâ€™ orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 2020, 43, 1717-1722.	3.3	15
115	Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S119-S123.	1.2	14
116	Multiple endocrine neoplasia type 2A. Cancer Genetics and Cytogenetics, 2003, 141, 157-159.	1.0	13
117	Graves orbitopathy: a perspective. Nature Reviews Endocrinology, 2009, 5, 312-318.	9.6	13
118	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Hellenic Endocrine Society.. Hormones, 2022, 21, 103-111.	1.9	13
119	Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace?. Clinical Endocrinology, 2000, 53, 1-2.	2.4	12
120	Medical Treatment for Thyroid-Associated Ophthalmopathy. Thyroid, 2002, 12, 241-244.	4.5	12
121	Milk alkali syndrome without the milk. BMJ: British Medical Journal, 2007, 335, 397-398.	2.3	12
122	Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. Journal of Endocrinological Investigation, 1999, 22, 30-4.	3.3	12
123	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey. Thyroid Research, 2022, 15, 3.	1.5	12
124	A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 577-586.	1.2	12
125	The Impact of Clinical Guidelines on Surgical Management in Patients with Thyroid Cancer. Clinical Oncology, 2003, 15, 485-489.	1.4	11
126	Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E458-E462.	3.6	11

#	Article	IF	Citations
127	Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit, 2017, 36, 159-169.	0.8	11
128	Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey. Endocrinologia, Diabetes Y NutriciÃ“n, 2022, 69, 520-529.	0.3	11
129	Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France. Annales D'Endocrinologie, 2022, 83, 27-34.	1.4	11
130	Antibodies to orbital tissues in thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1992, 126, 137-142.	3.7	10
131	Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose?. Clinical Endocrinology, 2002, 56, 689-691.	2.4	10
132	Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death. European Journal of Endocrinology, 2021, 184, C1-C3.	3.7	10
133	Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors. Pediatric Endocrinology Reviews, 2007, 4, 218-24.	1.2	10
134	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Czech Society of Endocrinology. BMC Endocrine Disorders, 2022, 22, 117.	2.2	10
135	General Management Plan. , 2007, , 88-95.		9
136	Is Recombinant Human TSH a Trigger for GravesÂ' Orbitopathy?. European Thyroid Journal, 2012, 1, 105-109.	2.4	9
137	Asymmetric Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2020, 11, 611845.	3.5	9
138	A survey on the psychological impact and access to health care of thyroid patients during the first SARSâ€COVâ€2 lockdown. Clinical Endocrinology, 2021, , .	2.4	9
139	Psoas abscess due to retroperitoneal tuberculous lymphadenopathy. Tubercle, 1988, 69, 299-301.	0.6	8
140	Lack of Antigenicity of Recombinant Human Thyrotropin After Multiple Injections in Patients with Differentiated Thyroid Cancer. Thyroid, 2000, 10, 623-623.	4.5	8
141	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. Thyroid, 2015, 25, 1181-1184.	4.5	8
142	Antithyroid drugs in Gravesâ€™ hyperthyroidism: differences between â€œblock and replaceâ€•and â€œtitrationâ€• regimes in frequency of euthyroidism and Gravesâ€™ orbitopathy during treatment. Journal of Endocrinological Investigation, 2021, 44, 371-378.	3.3	8
143	Biological activity of autoantibodies from patients with thyroid-associated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. The Quarterly Journal of Medicine, 1992, 84, 691-706.	1.0	8
144	Management plan and delivery of care in Gravesâ€™ ophthalmopathy patients. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 303-311.	4.7	7

#	Article	IF	Citations
145	Saving lives of inâ€patients with adrenal insufficiency: implementation of an alert scheme within the Newcastleâ€uponâ€Tyne Hospitals eâ€Prescribing platform. Clinical Endocrinology, 2014, 81, 937-938.	2.4	7
146	Phaeochromocytomas/paragangliomas and adverse clinical outcomes in patients with Neurofibromatosis type 1. Endocrine Connections, 2018, 7, R254-R259.	1.9	7
147	Management of recurrent pituitary cysts with pituitary-nasal drain. Pituitary, 2002, 5, 225-233.	2.9	6
148	2009 American Thyroid Association Guidelines on Thyroid Nodules. Clinical Oncology, 2010, 22, 469-471.	1.4	6
149	Orbital decompression for Gravesâ€™ orbitopathy in England. Eye, 2012, 26, 434-437.	2.1	6
150	Radioiodine Uptake in Normal Female Breasts and Liver of a Patient with Differentiated Thyroid Cancer Imaged by Whole Body Scanning. Thyroid, 2003, 13, 511-511.	4.5	5
151	Analysis of Peripheral Blood T-Cell Subsets in Active Thyroid-Associated Ophthalmopathy: Absence of Effect of Octreotide-LAR on T-Cell Subsets in Patients with Thyroid-Associated Ophthalmopathy. Thyroid, 2005, 15, 1073-1078.	4.5	5
152	The Management of Hypogonadism in Aging Male Patients. Postgraduate Medicine, 2009, 121, 113-121.	2.0	5
153	Optimizing the Management of Differentiated Thyroid Cancer. Clinical Oncology, 2000, 12, 363-364.	1.4	5
154	Evaluation of an on-call diabetes service in a large teaching hospital. Diabetic Medicine, 2000, 17, 386-389.	2.3	4
155	Detection of Hurthle Cell Carcinoma Using Sestamibi. Thyroid, 2008, 18, 575-576.	4.5	4
156	A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye, 2020, 34, 1662-1671.	2.1	4
157	Long-Term Effects of Hypoglycaemia on Cognitive Function and the Brain in Diabetes. , 0, , 285-307.		4
158	Glucocorticoids in the medical management of Graves' ophthalmopathy. Minerva Endocrinologica, 2003, 28, 223-31.	1.8	4
159	Raising awareness of Graves' orbitopathy with early warning cards. Clinical Endocrinology, 2017, 87, 853-859.	2.4	3
160	A decade of thyroidology. Hormones, 2018, 17, 491-495.	1.9	3
161	Do diabetes guidelines influence the content of referral letters by general practitioners to a diabetes specialist clinic?. Health Bulletin, 2000, 58, 322-7.	0.1	3
162	Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 2022, 97, 664-675.	2.4	3

#	Article	IF	Citations
163	Serum S-100Î² protein as a biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. Diabetic Medicine, 2001, 18, 1008-1008.	2.3	2
164	Thyrotoxicosis and Pregnancy. PLoS Medicine, 2005, 2, e370.	8.4	2
165	A Patient with Asymmetric Parotid Uptake on a Diagnostic Iodine-131 Scan during Thyroid Cancer Follow-Up. Thyroid, 2007, 17, 801-802.	4.5	2
166	Carcinoid Tumour in an Ileocystoplasty: A Reminder to Consider Native Bowel Disease in the Reconstructed Urinary Tract. British Journal of Medical and Surgical Urology, 2011, 4, 39-41.	0.2	2
167	An Unusual Presenting Symptom of GravesÂ' Disease: Myalgia. European Thyroid Journal, 2012, 1, 274-6.	2.4	2
168	Improving the prehospital safety of steroidâ€dependent patients in northern England: A hospitalâ€initiated ambulance service registration pathway. Clinical Endocrinology, 2017, 87, 881-882.	2.4	2
169	Differentiated thyroid cancer mortality by disease stage in northern England. Clinical Endocrinology, 2020, 93, 61-66.	2.4	2
170	Clinical Presentation and Natural History of Gravesâ€™ Ophthalmopathy. Growth Hormone, 2001, , 119-136.	0.2	2
171	Anti-mitochondrial antibodies in patients with Graves' disease may not signify primary biliary cirrhosis.. Postgraduate Medical Journal, 1994, 70, 17-18.	1.8	1
172	Role of serum thyroglobulin measurement in patients with thyroid nodules. Clinical Endocrinology, 2003, 59, 657-657.	2.4	1
173	Metachronous testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases. European Journal of Cancer Care, 2010, 19, 701-702.	1.5	1
174	Metastatic Midgut Carcinoid in the Myocardium. Clinical Nuclear Medicine, 2015, 40, e446-e447.	1.3	1
175	The Amsterdam Declaration on Graves' Orbitopathy. , 2017, , 338-344.		1
176	Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. Annals of Oncology, 2018, 29, viii470-viii471.	1.2	1
177	The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations. , 2018, , 7-15.		1
178	Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?. International Journal of Endocrinology and Metabolism, 2022, 20, .	1.0	1
179	A 69-Year-Old Female with Tiredness and a Persistent Tan. PLoS Medicine, 2005, 2, e229.	8.4	0
180	A 52-Year-Old Female with a Hoarse Voice and Tingling in the Hand. PLoS Medicine, 2007, 4, e29.	8.4	0

#	Article	IF	Citations
181	DeclaraciÃ³n de consenso del Grupo europeo sobre la orbitopatÃa de Graves (EUGOGO) sobre el tratamiento de la orbitopatÃa de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0
182	General Management Plan. , 2010, , 88-95.		0
183	The Amsterdam Declaration on Gravesâ€™ Orbitopathy. , 2010, , 265-270.		0
184	Rising Serum 25-Hydroxyvitamin D Levels After Weight Loss in Obese Women Correlate With Improvement in Insulin Resistance. Obstetrical and Gynecological Survey, 2011, 66, 23-24.	0.4	0
185	Clinical Spectrum of Graves Orbitopathy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 83-89.	0.5	0
186	Hypothyroxinemia, Hyperthyrotropinemia, and Radioiodine: Partners in Crime Against Graves Orbitopathy?. AACE Clinical Case Reports, 2015, 1, e145-e146.	1.1	0
187	Novel Immunomodulatory Treatment Modalities. , 2017, , 177-192.		0
188	Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.. Journal of Clinical Oncology, 2014, 32, 4111-4111.	1.6	0
189	Medical Management of Mild and Moderate to Severe Thyroid Eye Disease. , 2015, , 83-88.		0
190	Health care access of thyroid disease patients in Serbia during the COVID-19 pandemic. Journal of Endocrinological Investigation, 2022, , 1.	3.3	0
191	Adrenal Cortical Carcinoma. , 0, , 137-141.		0